Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Background

The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel from the Dutch societal perspective was investigated.

Methods

A cost-effectiveness analysis was conducted using efficacy, symptomatic skeletal-related event and safety data obtained from indirect treatment comparisons. Missing skeletal-related event data for cabazitaxel were conservatively assumed to be identical to radium-223. A Markov model combined these clinical inputs with Dutch-specific resource use and costs for metastatic castration-resistant prostate ca

SUBMITTER: Peters ML 

PROVIDER: S-EPMC5797195 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature